In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen

Virology

Volumn 240, Issue 2, 1998, Pages 304-315

  Le Borgne, Sylvie ^d   Mancini, Maryline ^a   Le Grand, Roger ^b   Schleef, Martin ^c   Dormont, Dominique ^b   Tiollais, Pierre ^a   Rivière, Yves ^d   Michel, Marie Louise ^a  

^a INSERM   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c QIAGEN GMBH   (Germany)

^d NONE

Author keywords

CTL; CTLp; Genetic vaccine; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus; Humoral response; Rhesus monkeys

Indexed keywords

EPITOPE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; FEMALE; GENE THERAPY; GENETIC VARIABILITY; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS ENVELOPE;

ANIMALIA; DNA VIRUSES; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA; PRIMATES;

EID: 0032518355     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8942     Document Type: Article

References (44)

1. Ando K., Guidotti L. G., Wirth S., Ishikawa T., Missale G., Moriyama T., Schreiber R. D., Schlicht H. J., Huang S., Chisari F. V. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cellsin vivo. J. Immunol. 152:1994;3245-3253.
2. Bergmann C., Stohlmann S. A., McMillan M. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein. Eur. J. Immunol. 23:1993;2777-2781.
3. Boyer J. D., Ugen K. E., Wang B., Agadjanyan M. G., Gilbert L., Bagarazzi M. L., Chattergoon M., Frost P., Javadian A., Williams W. V., Refaeli Y., Ciccareli R. B., McCallus D., Coney L., Weiner D. B. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 3:1997;526-532.
4. Buseyne F., Février M., Garcia S., Gougeon M. L., Rivière Y. Dual functions of a human immunodeficiency virus (HIV) specific cytotoxic T-lymphocytes (CTL) clone: Inhibition of HIV replication by non-cytolytic mechanisms and lysis of HIV-infected CD4+ cells. Virology. 225:1996;248-253.
5. Carmichael A., Jin X., Sissons P., Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type- 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:1993;249-256.
6. Chisari F. V. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:1995;29-60.
7. Cox G. J., Zamb T. J., Babiuk L. A. Bovine herpesvirus 1: Immune responses in mice and cattle injected with plasmid DNA. J. Virol. 67:1993;5664-5667.
8. Davis H. L., Michel M.-L., Whalen R. G. DNA based immunization for hepatitis B induces continuous secretion of antigen and high levels of circulating antibody. Hum. Mol. Genet. 2:1993a;1847-1851.
9. Davis H. L., Schirmbeck R., Reimann J., Whalen R. G. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum. Gene Ther. 6:1995;1447-1456.
10. Davis H. L., Whalen R. G., Demeneix B. A. Direct gene transfer into skeletal musclein vivo: Hum. Gene Ther. 4:1993b;151-159.
11. Donnelly J. J., Friedman A., Martinez D., Montgomery D. L., Shiver J. W., Motzel S. L., Ulmer J. B., Liu M. A. Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Nature Med. 1:1995;583-587.
12. Donnelly J. J., Ulmer J. B., Shiver J. W., Liu M. A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
13. Fazekas de st Groth S. The evaluation of limiting dilution assays. J. Immunol. Methods. 49:1982;R11-R23.
14. Fynan E. F., Webster R. G., Fuller D. H., Haynes J. R., Santoro J. C., Robinson H. L. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 90:1993;11478-11482.
15. Guidotti L. G., Ishikawa T., Hobbs M. V., Matzke B., Schreiber R., Chisari F. V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 4:1996;25-36.
16. Haynes B. F., Pantaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
17. Itoh Y., Takai E., Ohnuma H., Kitajima K., Tsuda F., Machida A., Mishiro S., Nakamura T., Miyakawa Y., Mayumi M. A synthetic peptide vaccine involving the product of the pre-S(2) region of the hepatitis B virus DNA: Protective efficacy in chimpanzees. Proc. Natl. Acad. Sci. USA. 83:1986;9174-9178.
18. Kalams S. A., Johnson R. P., Trocha A. K., Dynan M. J., Ngo H. S., D'Aquila R. T., Kurnick J. T., Walker B. Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocytes clones reveals a limited TCR repertoire. J. Exp. Med. 179:1994;1261-1271.
19. Koup R. A., Saffrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;6103-6110.
20. Kundu S. K., Merigan T. C. Relationship of HIV-1 provirus load, CD8+ CD11+ T cells and HIV-1 envelope-specific cytotoxic T lymphocytes in HIV-infected asymptomatic patients. Immunology. 83:1994;81-85.
21. Lekutis C., Shiver J. W., Liu M. A., Letvin N. L. HIV-1 env DNA vaccine administered to Rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete INF-γ and TNF-α J. Immunol. 158:1997;4471-4477.
22. Levy J. A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:1993;183-193.
23. Lu S., Arthos J., Montefiori D. C., Yasutomi Y., Manson K., Mustafa F., Johnson E., Santoro J. C., Wissink J., Mullins J. I., Haynes J. R., Letvin N. L., Wyand M., Robinson H. L. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:1996;3978-3991.
24. Major M. E., Vitvitski L., Mink M. A., Schleef M., Whalen R. G., Trepo C., Inchauspe G. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol. 69:1995;5798-5805.
25. Mancini M., Hadchouel M., Tiollais P., Pourcel C., Michel M.-L. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg transgenic mice: A possible way of circumventing "nonresponse" to HBsAg. J. Med. Virol. 39:1993;67-74.
26. McChesney M., Tanneau F., Regnault A., Sansonetti P., Montagnier L., Kieny M. P., Rivière Y. Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of theenv. Eur. J. Immunol. 20:1990;215-220.
27. Michel M.-L., Mancini M., Rivière Y., Dormont D., Tiollais P. T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles. J. Virol. 64:1990;2452-2455.
28. Michel M.-L., Mancini M., Sobczak E., Favier V., Guetard D., Bahraoui E. M., Tiollais P. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc. Natl. Acad. Sci. USA. 85:1988;7957-7961.
29. Michel M. L., Davis H. L., Schleef M., Mancini M., Tiollais P., Whalen R. G. DNA-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. USA. 92:1995;5307-5311.
30. Neurath A. R., Kent S. B. H., Strick N., Taylor P., Stevens C. E. Hepatitis B virus contains pre-S gene-encoded domains. Nature. 315:1985;154-156.
31. Pedroza Martins L., Lau L. L., Asano M. S., Ahmed R. DNA vaccination against persistent viral infection. J. Virol. 69:1995;2574-2582.
32. Penna A., Artini M., Cavalli A., Levero M., Bertoletti A., Pilli N., Chisari F. V., Rehermann B., Delprete G., Fiaccadori F., Ferrari C. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest. 98:1996;1185-1194.
33. Prince A. M., Whalen R., Brotman B. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine. 15:1997;916-919.
34. Rivière Y., Tanneau-Salvadori F., Regnault A., Lopez O., Sansonetti P., Guy B., Kieny M. P., Fournel J. J., Montagnier L. HIV-specific cytotoxic responses of seropositive individuals: Distinct types of effector cells mediate killing of targets expressinggagenv. J. Virol. 63:1989;2270-2277.
35. Schirmbeck R., Melber K., Reimann J. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur. J. Immunol. 25:1995;1063-1070.
36. Schlienger K., Mancini M., Rivière Y., Dormont D., Tiollais P., Michel M.-L. Human immunodeficiency virus type-1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J. Virol. 66:1992;2570-2576.
37. Schlienger K., Mancini M., Tiollais P., Michel M.-L. Recombinant hepatitis B surface antigen as carrier of human immunodeficiency virus (HIV) epitopes: Towards a dual immunogenic vaccine. Modern Vaccinology. 1994;Plenum Medical Book Co. New York, London. p. 169-179.
38. Schorr J., Moritz P., Seddon T., Schleef M. Plasmid DNA for human gene therapy and DNA vaccines. Production and quality assurance. Ann. N. Y. Acad. Sci. 772:1995;271-273.
39. Takahashi H., Cohen J., Hosmalin A., Cease K. B., Houghten R., Cornette J. L., Delisi C., Moss B., Germain R. N., Berzofsky J. A. An immunodominant epitope of the HIV envelope glycoprotein gp160 recognized by class 1 MHC molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 85:1988;3105-3109.
40. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., De Witt C. M., Friedman A., Hawe L. A., Leander K. R., Martinez D., Perry H. C., Shiver J. W., Mongomery D. L., Liu M. A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
41. Venet A., Bourgault I., Aubertin A.-M., Kieny M.-P., Lévy J.-P. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virus (SIV) proteins in SIV-infected macaques. J. Immunol. 148:1992;2899-2908.
42. Xiang Z. Q., Spitalnik S., Tran M., Wunner W. H., Cheng J., Ertl H. C. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 199:1994;132-140.
43. Yasutomi Y., Koenig S., Woods R. M., Madsen J., Wassef N. M., Alving C. R., Klein H. J., Nolan T. E., Boots L. J., Kessler J. A., Emini E. A., Conley A. J., Letvin N. L. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous cell-free simian immunodeficiency virus challenge. J. Virol. 69:1995;2279-2284.
44. Yasutomi Y., Reimann K. A., Lord C. I., Miller M. D., Letvin N. L. Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J. Virol. 67:1993;1707-1711.